The monthly European Industrial Pharmacists' newsletter November 2021

Technology & Research

Commission's portfolio of 10 most promising Covid-19 treatments

Antiviral monoclonal antibodies, oral antivirals and immunomodulators are the 3 most promising categories of therapeutics identified with respect to the rapid development and approval of new options for the treatment of Covid-19. Selected candidates will now follow the formal regulatory assessment and approval procedure >>

Regulatory Affairs

EMA's new role & a pilot project for repurposing of medicines

European Parliament enlarges EMA's action to the management of crisis preparedness, with a special focus on the availability of medicines and medical devices needed to face health emergencies. A pilot project was launched by the Agency to support the repurposing of off-patent medicines. >>

Business & Policies

A step forward towards the African Medicines Agency

The operative phase of implementation of AMA by the African Union started. The newly born Agency will be responsible for the promotion and coordination of regulatory activities among the adhering countries, aiming to reach a better harmonisation of the framework for medicines' development, manufacturing and approval in Africa. >>

EU Focus

Steps forward towards the new framework for HTA

The HTA regulation is about to come into force 3 years after its publication in the EU Official Journal. To support the implementation phase, the new Heads of Agencies Group has been created; EUnetHTA 21 consortium has signed a Service Contract with HaDEA and launched the first Open Call targeted to the pharmaceutical industry. >>

News from EIPG

Consultation on the revision of the pharmaceutical legislation

In November 2020, the Commission published a Communication on a Pharmaceutical Strategy for Europe. Commission is evaluating the general pharmaceutical legislation and assessing the impacts of possible changes in the legislation as described in the relevant inception impact assessment. >>